Moneycontrol PRO
Upcoming Webinar:Prashant Shah explains ‘Irrelevance of Bull & Bear Markets for Success in Technical Analysis’. Register For Free!
you are here: HomeNewsBusiness

LUPIN Q4 PAT seen up 3.5% YoY to Rs. 317.2 cr: Sharekhan

Net Sales are expected to increase by 3.5 percent Y-o-Y (down 0.9 percent Q-o-Q) to Rs. 3,979 crore, according to Sharekhan.

April 12, 2021 / 08:40 PM IST
Lupin | Company received approval from USFDA for Sulfamethoxazole and Trimethoprim Oral Suspension, which is used to treat bacterial infections.

Lupin | Company received approval from USFDA for Sulfamethoxazole and Trimethoprim Oral Suspension, which is used to treat bacterial infections.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sharekhan has come out with its fourth quarter (January-March’ 21) earnings estimates for the Pharmaceuticals sector. The brokerage house expects LUPIN to report net profit at Rs. 317.3 crore up 3.5% year-on-year (down 27.6% quarter-on-quarter).


Net Sales are expected to increase by 3.5 percent Y-o-Y (down 0.9 percent Q-o-Q) to Rs. 3,979 crore, according to Sharekhan.


Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Broker Research

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark